Skip to main content

Table 3 Summary of new metastases by sitea based on independent review (intent-to-treat populations)

From: “New” metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

Parameter Study 301 Study 305/EMBRACE
Eribulin Capecitabine Eribulin TPC
(n = 554) (n = 548) (n = 508) (n = 254)
Patients whose disease progressed owing to new metastases, n (%) 216 (39.0 %) 204 (37.2 %) 139 (27.4 %) 68 (26.8 %)
Sites of new metastasesb, n (%)
 Liver 72 (33.3) 80 (39.2) 41 (29.5) 30 (44.1)
 Lung 30 (13.9) 33 (16.2) 8 (5.8) 4 (5.9)
 Lymph nodes 7 (3.2) 3 (1.5) 16 (11.5) 6 (8.8)
 Bone 19 (8.8) 16 (7.8) 7 (5.0) 2 (2.9)
 Skin 66 (30.6) 62 (30.4) 3 (2.2) 1 (1.5)
 CNS (brain/spine) 4 (1.9) 17 (8.3) 7 (5.0) 0
 Breast 12 (5.6) 7 (3.4) 3 (2.2) 0
 Chest wall 9 (4.2) 4 (2.0) 25 (18.0) 5 (7.4)
 Other 6 (2.8) 13 (6.4) 5 (3.6) 4 (5.9)
  1. CNS central nervous system, EMBRACE Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389, TPC treatment of physician’s choice
  2. aOnly the first new metastasis observed is recorded. If there were multiple new metastases observed at the same time and all determined as earliest, all new metastasis sites were summarized
  3. bPercentages for metastasis sites are based on the number of patients in each study arm whose disease progressed owing to new metastases